Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature

Clin Lung Cancer. 2018 Sep;19(5):e717-e720. doi: 10.1016/j.cllc.2018.05.010. Epub 2018 May 26.

Authors

Alexander Vittorio¹, Rajiv Sharma², Dylan Siejka², Keshav Bhattarai², Ashutosh Hardikar²

Affiliations

¹ Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia; Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia. Electronic address: alexander.vittorio@health.qld.gov.au.
² Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia.

PMID: 29937384
DOI: 10.1016/j.cllc.2018.05.010

No abstract available

Keywords: Checkpoint; Immune; Pericardiocentesis; Tamponade; Window.

Publication types

Case Reports
Review

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary
Aged
Cardiac Tamponade / chemically induced*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Nivolumab / adverse effects*
Pericardial Effusion / chemically induced*
Prognosis
Recurrence

Substances

Nivolumab